RFWD3 Reprograms Nucleotide Metabolism Through PHGDH to Induce Chemoresistance In Osteosarcoma
Advanced Science · 2025-04 · 12 (16)
DOI: 10.1002/advs.202410937 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 28.02.2025. Verfasst von Wenchao Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, 410011, China. Hauptthemen laut MEDLINE: Osteosarcoma, Drug Resistance, Neoplasm, Nucleotides, Phosphoglycerate Dehydrogenase. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Foundation of China, National Key Research and Development Program of China, Science and Technology Innovation Program of Hunan Province.
Abstract (Originalsprache)
Chemoresistance represents a major challenge for osteosarcoma treatment. Despite the improved knowledge of cancer biology, the core determinants of cisplatin (DDP) resistance in osteosarcoma remain unclear and deserve further exploration. Here, RFWD3 is identified as a key regulator of DDP sensitivity in osteosarcoma using a genome‐wide CRISPR screen. It is demonstrated that RFWD3 is overexpressed in post‐chemotherapy osteosarcoma tissues compared to pre‐chemotherapy tissues. Knocking out RFWD3 increased the sensitivity of osteosarcoma cells to DDP treatment. Mechanistically, RFWD3 bound to and ubiquitinated PHGDH at the Lys137 residue, promoting its degradation and conserving cellular oxidized nicotinamide adenine dinucleotide (NAD + ). The resulting surplus of NAD + enhanced the TCA cycle, leading to increased production of aspartic acid and glutamic acid for de novo nucleotide biosynthesis. In addition, virtual screening techniques are employed to identify Lomitapide as a specific inhibitor of the RFWD3‐PHGDH interaction, capable of disrupting the binding between RFWD3 and PHGDH. It is found that Lomitapide exhibits a significant synergistic anti‐osteosarcoma effect when combined with DDP. In conclusion, a specific role of RFWD3 in regulating nucleotide metabolism is revealed and comprised of targetable candidates for overcoming chemoresistance in osteosarcoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
- Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital, Changsha, 410011, China.
- Department of Neurosurgery, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
- Changsha Medical University, Changsha, 410219, China.
- Shenzhen Research Institute of Central South University, Guangdong, 518063, China.
- FuRong Laboratory, Changsha, Hunan, 410078, China.
ORCID-Profile: Zhihong Li
Förderung
- National Natural Foundation of China
- National Key Research and Development Program of China
- Science and Technology Innovation Program of Hunan Province
- Hunan Provincial Natural Science Foundation of China
- Hunan Provincial Administration of Traditional Chinese Medicine Project
- Scientific Research Program of Hunan Provincial Health Commission
- Hunan Provincial Health High-Level Talent Scientific Research Project
- State-funded Postdoctoral Researchers Plan of China
Zitieren
APA
Zhang, W., Yin, C., Qi, L., Liu, Z., Xu, R., Tu, C., & Li, Z. (2025). RFWD3 Reprograms Nucleotide Metabolism Through PHGDH to Induce Chemoresistance In Osteosarcoma. Advanced Science, 12(16). https://doi.org/10.1002/advs.202410937
Vancouver
Zhang W, Yin C, Qi L, Liu Z, Xu R, Tu C, et al. RFWD3 Reprograms Nucleotide Metabolism Through PHGDH to Induce Chemoresistance In Osteosarcoma. Advanced Science. 2025;12(16). doi:10.1002/advs.202410937
BibTeX
@article{Zhang2025,
author = {Zhang, Wenchao and Yin, Chi and Qi, Lin and Liu, Zhongyue and Xu, Ruiling and Tu, Chao and Li, Zhihong},
title = {RFWD3 Reprograms Nucleotide Metabolism Through PHGDH to Induce Chemoresistance In Osteosarcoma},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {16},
doi = {10.1002/advs.202410937}
}
EUVIMED